All Terrain Financial Advisors’s PDL BioPharma, Inc. PDLI Stock Holding History

All Terrain Financial Advisors’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-14,000	Closed	-$41K	–	263
2018 Q1	$41K	Buy	+14,000	New	+$38.2K	0.02%	220

Other funds holding PDLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

All Terrain Financial Advisors's PDLI Position: Q2 2018 in Review

All Terrain Financial Advisors sold out of PDL BioPharma, Inc. (PDLI) in Q2 2018, closing a stake of 14,000 shares — an estimated $41K sold.

All Terrain Financial Advisors first reported a position in PDLI in Q1 2018 and held it in 1 quarter. The position peaked at $41K in Q1 2018. 163 funds tracked by Wall St. Rank hold PDLI as of Q2 2018.

All Terrain Financial Advisors reported no remaining PDL BioPharma, Inc. position as of Q2 2018 after selling out during the quarter.
All Terrain Financial Advisors sold 14,000 PDL BioPharma, Inc. shares in Q2 2018, an estimated $41K.
All Terrain Financial Advisors first reported a position in PDL BioPharma, Inc. in Q1 2018 and held it in 1 quarter.
All Terrain Financial Advisors's PDL BioPharma, Inc. position peaked at $41K in Q1 2018.
163 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q2 2018.

Based on All Terrain Financial Advisors's 13F filing for Q2 2018, filed 9 Aug 2018.